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ABSTRACT 
The aim of present study was to prepare buffered tablets of acid labile drug, Rabeprazole sodium for oral administration using buffering agents 
to protect a drug from gastric fluid. Rabeprazole belongs to a class of antisecretory compounds (substituted benzimidazole proton-pump 
inhibitors) that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but suppress gastric acid secretion by inhibiting 
the gastric H+, K+ATPase at the secretory surface of the gastric parietal cell. Rabeprazole blocks the final step of gastric acid secretion. The 
tablets were prepared by direct compression and wet granulation method. The formulations contain water soluble buffers such as sodium 
bicarbonate and trisodium phosphate as well as water insoluble buffers as magnesium oxide, magnesium hydroxide and calcium carbonate and 
crospovidone as superdisintegrant. Preformulation studies like angle of repose, bulk density, tapped density, Carr’s index, hausner’s ratios, DSC 
and drug/excipient compatibility study were conducted and evaluated for hardness, friability, weight variation, drug content, disintegration 
and in-vitro dissolution. In the present study, pH of F6 batch was found to be optimum and disintegration time is 42 sec. The drug release was 
found to show maximum drug release in case of F6 with 99.3% in 60 minutes. In case of stability studies study of the optimized batch, all the 
results were found to be satisfactory and within limits. There were no significant changes after the period of 1 month study. 
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INTRODUCTION 
Rabeprazole sodium drug is a sodium salt of 2-((4-(3-
methoxypropoxy)-3-methylpyridin-2-yl) methylsulfinyl)-1H-
benzo[d]imidazole belongs to a class of proton pump 
inhibitors. It suppress gastric acid secretion by specifically 
inhibiting the H+/K+- ATPase enzyme system at the secretory 
surface of the gastric parietal cell1.  Peptic ulcer disease 
comprises a group of chronic ulcerative conditions that 
primarily affect the gastric mucosa and proximal duodenum. 
The drug like H2 blockers cimetidine, ranitidine and 
famotidine reduce the amount of acid produced by stomach. 
But Proton Pump Inhibitors (PPIs) are a group of drugs 
whose main action is pronounced and long-lasting reduction 
of gastric acid production. These drugs are metabolized in 
the parietal cells to active sulfonamide metabolites that 
inactivate the sulfhydryl group of the proton pump, thus 
reducing the hydrogen ion secretion2,3. Most of the PPIs are 
formulated in an enteric-coated solid dosage form (either a 
delayed-release capsule or tablet) or as an intravenous 
solution. There are some problems associated with enteric-
coated preparations as dissolution of the enteric coating is 
pH-dependent and gastric empting time. pH profile of the 
gastrointestinal tract in an individual is variable at different 
times and is dependent on numerous physiological factors 
(e.g., the fed or fasted state), variable dissolution times for 
the enteric coat and variable pharmacokinetic profiles of 
individuals may affects4-6. The acid-labile drugs for oral 
administration may also be protected from gastric acidity by 
neutralizing the pH of the gastric fluid. So the current 
frontier in PPI therapy is immediate-release tablet combined 
with buffering agents which prevent degradation of drug by 
neutralizing the pH of stomach before absorption and 
protect the drug from low pH. Such dosage forms are known 
as buffered tablet and such tablet is advantageously devoid 
of any enteric coating or delayed or sustained-release 
delivery7,8 . 
MATERIAL AND METHOD 
Material  
Rabeprazole sodium was obtained as gift sample from Cadila 
Healthcare Ltd., Ahmedabad. All chemicals were used of 
pharmaceutical grade obtained as gift sample from apex 
pharmaceutical, Chennai. 
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Method 
Preformulation study 
Melting point determination 
Melting point of Rabeprazole was determined by open 
capillary method.  
Determination of partition coefficient 
25mg of drug was taken in three separating funnels. The 
separating funnels were shaken for 2hrs in a wrist action 
shaker for equilibration. Two phases were separated and the 
amount of the drug in aqueous phase was analyzed 
spectrophotometrically. The partition coefficient of the drug 
in phases was calculated by using formula. 
Determination of λmax 
A solution of rabeprazole containing the concentration 
10µg/ml was prepared in 0.1 M HCL and UV spectrum was 
taken using Shimadzu (UV-1800) double beam 
spectrophotometer. The solution was scanned in the range of 
200- 400 nm. 
Drug – excipient interaction studies by FTIR 
Infra-red spectra matching approach was used for the 
detection of any possible chemical reaction between the drug 
and the excipients. A physical mixture (1:1) of drug and 
excipients was prepared and mixed with suitable quantity of 
potassium bromide. About 100mg of this mixture was 
compressed to form a transparent pellet using a hydraulic 
press at 10 tones pressure. It was scanned from 4000 to 150 
cm-1 in a shimadzu FTIR spectrophotometer. The IR 
spectrum of the physical mixture was compared with those 
of pure drug and excipients and matching was done to detect 
any appearance or disappearance of peaks. 
Preparation of standard calibration curve of rabeprazole 
sodium in 0.1M HCL  
100mg of drug was accurately weighed and dissolved in 
100ml 0.1N HCl in 100 ml volumetric flask, to make 
(1000μg/ml) standard stock solution (1). Then 10 ml stock 
solution (1) was taken in another 100 ml volumetric flask to 
make (100μg/ml) standard stock solution (2), then again 0.5, 
1, 1.5, 2, 2.5and 3 ml of stock solution (2) was taken in 
another 10 ml volumetric flask and then final concentrations 
were prepared 5, 10, 15, 20, 25 and 30μg/ml with 0.1N HCl. 
The absorbance of standard solution was determined using 
UV/VIS spectrophotometer (Shimdzu Jappan) at 275.43nm. 
Linearity of standard curve was assessed from the square of 
correlation coefficient (r2) which determined by least-square 
linear regression analysis. 
Formulation development of rabeprazole sodium 
buffered tablets 
Selection of buffers 
Water soluble buffers such as sodium bicarbonate and 
trisodium phosphate as well as water insoluble buffers as 
magnesium oxide, magnesium hydroxide and calcium 
carbonate were tested for their acid neutralizing capacity by 
adding a fixed dose of the buffer to a sample of artificial 
gastric juice. The basal stomach fluid contains 9.6 ml of 0.1 N 
HCl and releases 0.5 ml of 0.1 N HCl per minute. The buffer 
was added to the basal simulated gastric fluid containing 9.6 
ml of 0.1 N HCl + 210 ml of water and titrated with excess 
acid (0.1 N HCl) at the rate of 0.5 ml/ minute for a period of 1 
hour (total volume = 250 ml). The buffer(s) which 
maintained a pH above 6.0 at the excess acid secretion were 
selected.  
Formulation of inner core tablet of the tablet-in-tablet 
by direct compression 
Rabeprazole sodium, sodium bicarbonate, mannitol, hydroxy 
propyl cellulose, crospovidone as shown in Table 1 were co-
sifted through 40 # sieve on a vibratory sifter and collected. 
Iron oxide red was sifted through 100 # sieve and collected. 
The sifted materials were loaded into the octagonal blender 
and mixed for 5 minutes. To the above mixed blend, colloidal 
silicon dioxide and magnesium stearate were added, blended 
for 5 minutes and compressed by using 7 mm, round shaped 
flat- faced punches on a Rimek 16 station rotary compression 
machine with “B & D” tooling. 
 
Table 1 Physical characteristics of Inner core tablet 
S.No Ingredients A 1 A 2 A 3 A 4 
mg/Tab mg/Tab mg/Tab mg/Tab 
1.  Rabeprazole sodium 20.00 20.00 20.00 20.00 
2.  Mannitol 49.60 49.80 48.80 47.80 
3.  Hydroxy propyl cellulose 4.00 3.00 2.00 2.00 
4.  Crospovidone 4.00 4.00 5.00 6.00 
5.  Colloidal silicon dioxide 0.50 1.00 1.50 1.50 
6.  Magnesium stearate 1.20 1.50 2.00 2.00 
7.  Sodium bicarbonate 20.00 20.00 20.00 20.00 
8.  Iron oxide red 0.70 0.70 0.70 0.70 
9.  Total weight 100.00 100.00 100.00 100.00 
 
Formulation of outer layer buffer blend of the Tablet-in-
Tablet by Wet granulation 
Sodium bicarbonate, magnesium oxide, mannitol were co-
sifted through 40 # sieve. Hydroxyl propyl cellulose, 
crospovidone and aerosil were sifted individually through 
40 # sieve and collected separately. Magnesium stearate was 
sifted through 60 # sieve. Binder solution was prepared by 
adding half quantity of hydroxy propyl cellulose to the 
weighed quantity of water (350 ml/1000 tab) under 
constant stirring for 30 minutes. The sifted sodium 
bicarbonate, magnesium oxide, mannitol and half quantity of 
crospovidone were loaded into the Rapid Mixer Grinder 
bowl and mixed for 10 minutes by keeping impeller slow 
and chopper off. The binder solution was slowly added to 
the dry mix and the wet mass was kneaded with impeller 
and chopper both at fast speed and dried in hot air oven at 
500C till the loss on drying of the dried granules become not 
more than 2% at 1050C.Semidried granules were sifted 
through 20 # sieve. To the dried granules the remaining half 
quantity of hydroxyl propyl cellulose and crospovidone were 
added and blended for 5 minutes in the octagonal blender. 
Colloidal silicon dioxide and magnesium stearate was added 
to the pre-lubricated blend and mixed for 5 minutes. 
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Formulation of Tablet-in-Tablet 
Formulation of tablet in tablet is shown in Table 2. Selected 
punches and dies (12 mm round SC) were fixed to the 
compression machine. 350 mg of buffer composition was 
filled into the die cavity of rotary press and core tablet was 
placed at the center and filled with remaining 350 mg of 
buffer composition then finally compressed into a tablet.
 
Table 2 Physical characteristics of Tablet-in-Tablets 
S.No Ingredients F 1 F 2 F 3 F 4 F 5 F 6 
mg/tab mg/tab mg/tab mg/tab mg/tab mg/tab 
1.  Inner core tablet A 4 A 4 A 4 A 4 A 4 A 4 
2.  Sodium bicarbonate 300.00 300.00     
3.  Trisodium phosphate   200.00 250.00 200.00 250.00 
4.  Magnesium oxide (heavy) 250.00 300.00   250.00 300.00 
5.  Magnesium hydroxide   300.00 350.00   
6.  Mannitol 83.50 22.00 113.50 6.50 152.00 52.00 
7.  Hydroxy propyl cellulose 28.00 31.50 35.00 38.50 42.00 42.00 
8.  Crospovidone 28.00 35.00 38.50 42.00 42.00 42.00 
9.  Colloidal silicon dioxide 3.50 4.50 6.00 6.00 7.00 7.00 
10.  Magnesium stearate 7.00 7.00 7.00 7.00 7.00 7.00 
 
Evaluation of Tablets 
All the tablets were evaluated for different parameters as 
thickness, hardness, friability, uniformity of weight, 
disintegration time, drug content and in vitro dissolution 
study. 
Weight variation 
Randomly selected twenty tablets were weighed individually 
and together in a single pan balance. The average weight was 
noted and standard deviation calculated. The tablets pass the 
test if not more than two tablets fall outside the percentage 
limit and none of the tablet differs by more than double 
percentage limit. 
PD = [(Wavg – Winitial) / (Wavg)] x 100 
Where, PD = Percentage deviation,,Wavg = Average weight of 
tablet,, Winitial = Individual weight of tablet 
Thickness 
The thickness and diameter of tablets was determined using 
Vernier Caliper. Twenty tablets from each batch were used 
and average values were calculated. 
Hardness 
The Monsanto hardness tester was used to determine the 
tablet hardness. The tablet was held between affixed and 
moving jaw. Scale was adjusted to zero; load was gradually 
increased until the tablet fractured. The value of the load at 
that point gives a measure of the hardness of the tablet. It is 
expressed in kg/cm2. For each formulation, the hardness of 
six tablets was determined and average value was calculated. 
Drug content 
Tablets were crushed and the powder equivalent to 100mg 
of drug were accurately weighed and transferred to 50 ml 
volumetric flask. To this flask, sufficient amount of distilled 
water was added to dissolve the tablets completely. Then, 
the volume of flask was made up to the mark with same 
solvent. From this solution, 1ml of the sample was pipetted 
out and transferred to 10 ml volumetric flask. The volume in 
the second flask was made up to the mark with distilled 
water. From this 0.6ml, 0.8ml and 1ml samples were 
withdrawn and volume was made up to 10ml to maintain 
concentration within the beer’s range. This final diluted 
solution was estimated UV spectrophotometrically at 275.43 
nm. 
Friability 
Twenty tablets samples were weighed accurately and placed 
in friabilator (Roche Friabilator). After the given 
specification (4 min at 25 rpm), loose dust was removed 
from the tablets. Finally tablets were weighed. The loss in 
weight indicates the ability of the tablets to withstand this 
type of wear. The % friability was then calculated by: 
% Friability = (Loss in weight / Initial weight) × 100  
Disintegration test 
Disintegration is evaluated to ensure that the drug substance 
is fully available for dissolution and absorption from the 
gastrointestinal tract. Disintegration test was carried out 
using tablet disintegration test apparatus (EI Instrument, 
India) using 0.1 N HCl without disk at room temperature 
(37±2C). 
Acid neutralizing capacity 
Accurately weighed quantity, equivalent to the minimum 
labeled dosage of tablet in tablet was transferred to a 250 ml 
beaker, to this 10 ml of water was added and swirled gently. 
The walls of the beaker were washed with 60 ml of water 
and mixed don the magnetic stirrer for 1 minute. 30 ml of 1 N 
HCl was pipette out into the test preparation and stirred  
continuously for 15 minutes and excess hydrochloric acid 
was titrated with 0.5 N NaOH to attain a stable pH of 3.5. The 
number of mEq of acid consumed was calculated by the 
formula (USP-NF 26). 
Differential scanning calorimeter (DSC) 
The physical state of drug was analyzed by DSC. The 
thermograms of Rabeprazole and with different polymers 
were obtained at a scanning rate of 10°C/min conducted 
over a temperature range of 25–350ºC. 
In vitro drug release studies 
In vitro drug release studies were carried out in 900 ml of 
0.1M HCl for the first 2 h using a USP XXII type 1 dissolution 
apparatus (Electrolab TDT-08L) at 60 rpm and 37 ± 0.5 °C. At 
predetermined time intervals during the dissolution test, 
samples (10 ml) were withdrawn for assay and replaced 
with equivalent volume of fresh medium to maintain 
conditions. All dissolution studies were performed in 
triplicate. The samples were filtered, diluted appropriately 
and then analyzed spectrophotometrically (Systronics, India) 
for Rabeprazole at 275.43 nm. 
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Kinetic analysis of dissolution data 
The release data were fitted to five kinetic models, viz, zero-
order, first-order, Higuchi and Korsmeyer-Peppas to 
determine drug release mechanism. 
Stability studies of the tablets 
For the prepared tablets, the stability studies were carried 
out at intermediate and accelerated conditions for a period 
of one month. At the end of study period the samples was 
analyzed by appropriate methods to determine the stability 
of formulation. 
RESULT AND DISCUSSION 
The melting point of rabeprazole was found to be 140-141oC. 
Solution was scanned under UV-Vis Spectrophotometer and 
λmax was determined. It was found to be 275.43 nm Fig.1. 
Partition coefficient of rabeprazole 0.1M HCL was found to be 
1.16. From the spectra of rabeprazole, physical mixture of 
drug and selected ingredients was observed that all 
characteristic peaks of rabeprazole were present in the 
combination spectrum, thus indicating compatibility 
between drug and selected ingredients. FTIR spectra were 
shown in Fig.2 and 3. DSC Thermo grams of rebeprazole 
sodium and with HPMC were obtained showed that no 
significant differences were observed Fig. 4 and 5. Different 
buffering agents and alkaline agents (Sodium bicarbonate, 
Trisodium phosphate, Magnesium oxide (heavy), Magnesium 
hydroxide) are used for neutralizing pH of SGF and there 
combination also tried for same shown in Table 3. The 
powder blend of the all designed formulations containing 
rebeprazole sodium were evaluated for parameters like 
angle of repose was found to be 39.13, 36.24, 33.87 and 
32.11, Bulk density was found to be 0.789, 0.784, 0.699 and 
0.776g/cm3, tapped density 1.067 1.078 1.666
 1.079g/cm3, Hausner’s ratio1.34, 1.32, 1.35 and 
1.31 Carr’s index 26.89, 26.60, 26.45 and 26.75were found 
for A1, A2, A3 and A4 formulation respectively and reported 
in Table 4. Physical characteristics of inner core tablet of 
rabeprazole were given in Table 5. The formulated tablets 
were evaluated for their organoleptic characters. The tablets 
are round shaped, biconvex, round in shape and white in 
colour. All the tablets showed elegance in appearance. 
Thickness  of the  tablets  was  found  to  be  in the  range  of  
5.3±0.03mm to5.5±0.03mm. The results showed that the 
thickness of all formulated tablets was found to be uniform. 
The hardness of the tablets was measured by Monsonto 
hardness tester. The hardness of all the formulations was 
found to be in the range of 5to9kg/cm2. It indicates all the 
tablets have adequate mechanical strength. Twenty tablets of 
each formulation were selected for weight variation test. The 
accepted percentage deviation was ±7.5 for 130-324mg 
weight tablets. The results showed that weight variation was 
ranging from 798 ± 5 to 802 ± 5 mg. It was within the I.P. 
limit and all the tablets passed the weight variation test. 
Friability test was carried out by Roche friabilitor. The 
maximum weight loss should be not more than 1%. The 
maximum and minimum friability values among 6 
formulations were found to be in the range of 0.36 to 1.08. 
Hence all the tablets passed the friability test. The 
disintegration time of core tablets were found in the range 
between 42 to110sec. The results revealed that the 
disintegration time was within the acceptable limits. The 
assay of Rabeprazole sodium tablets were found in the range 
between 98.04 and 101.20. The acceptable limit of 
Rabeprazole sodium content as per I.P. is 90 to 110%. The 
results revealed that the assay of rabeprazole sodium was 
within the acceptable limits. In the present study, pH of F6 
batch was found to be optimum and disintegration time is 42 
sec. In-vitro drug release studies were done for the selected 
formulations from each batch. The drug release was found to 
show maximum drug release in case of F6 with 99.3% in 60 
minutes as shown in table 6 and Fig 6. All formulations 
showed good acid neutrizing capacity in the range of 16.57 to 
24.72 m.Eq Table 7. Stability testing was conducted to know 
how the quality of a drug substance or drug product varies 
with time under the influence of a variety of environmental 
factors. In the present stability study of the optimized batch, 
all the results were found to be satisfactory and within limits. 
There were no significant changes after the period of 1 
month study Table 8. 
 
 
 
Figure1 UV spectra of Rabeprazole 
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Figure 2FTIR spectra of Rabeprazole sodium 
 
Figure 3 FTIR spectra of Rabeprazole sodium tablet 
 
Figure 4 DSC of Rabeprazole sodium 
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Figure 5 DSC of formulation with HPMC 
Table 3 Buffering capacity of different buffers 
Name of Buffering agent Buffering agent conc. 
Sodium bicarbonate 300.00 300.00     
Trisodium phosphate   200.00 250.00 200.00 250.00 
Magnesium oxide (heavy) 250.00 300.00   250.00 300.00 
Magnesium hydroxide   300.00 350.00   
pH Achieve 5.73 6.51 5.42 5.95 3.14 4.98 
 
Table 4 Evaluation of powder blend 
 Parameters Formulations 
A 1 A 2 A 3 A 4 
BulkDensity(g/cm
3
) 0.789 0.784 0.699 0.776 
TappedDensity(g/cm
3
) 1.067 1.078 1.666 1.079 
AngleofRepose(θ) 39.13 36.24 33.87 32.11 
Carrsindex(%) 26.89 26.60 26.45 26.75 
Hausnersratio(HR) 1.34 1.32 1.35 1.31 
 
Table 5 Physical characteristics of Inner core tablet of Rabeprazole 
S.No Parameter Formulations 
A 1 A 2 A 3 A 4 
1.  Appearance Brick red colour, 
round shaped tablets 
Brick red colour, 
round shaped tablets 
Brick red colour, 
round shaped tablets 
Brick red colour, 
round shaped tablets 
2.  Weight variation (mg) 101 ± 5.0 98 ± 5.0 102 ±5.0 99 ± 5.0 
3.  Thickness(mm) 2.2 ± 0.3 2.1 ± 0.3 2.2 ± 0.3 2.0 ± 0.3 
4.  Hardness ( kg/cm2) 3.0-4.0 2.0-3.0 2.0-3.0 2.0-3.0 
5.  Friability (%) 0.04 0.07 0.05 0.06 
6.  Disintegration(Sec.) 30 42 45 25 
* All the values are expressed as mean ± SD; n=3. 
Table 6 Physical characteristics of buffered tablets of Rabeprazole 
S.No Parameter Formulations 
F 1 F 2 F 3 F 4 F 5 F 6 
1 Appearance White colour, 
round shaped, 
biconvex 
White colour, 
round shaped, 
biconvex 
White colour, 
round shaped, 
biconvex 
White colour, 
round shaped, 
biconvex 
White colour, 
round shaped, 
biconvex 
White colour, 
round shaped, 
biconvex 
2 Weight variation 
(mg) 
802 ± 5.0 799 ±5.0 804 ±5.0 803 ±5.0 798±5.0 801±5.0 
3 Thickness (mm) 5.5 ± 0.3 5.3 ±0.3 5.5±0.3 5.4 ± 0.3 5.3±0.3 5.4 ± 0.3 
4 Hardness    
(kg/cm2) 
5.0-6.0 8.0-9.0 7.0-8.0 8.0-9.0 8.0-9.0 8.0-9.0 
5 Friability (%) 1.08 0.82 0.80 0.63 0.37 0.36 
6 Disintegration 
(Sec.) 
110 60 70 45 48 42 
7 Drug content (%) 98.04 100.07 99.35 101.20 98.92 99.02 
* All the values are expressed as mean ± SD; n=3 
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Figure 6 Percent drug release study in simulated gastric 
fluid 
Table 7 Test for acid neutralizing capacity of 
formulations 
S. No. Formulation Acid Neutralizing 
Capacity (m.Eq.) 
1.  F1 18.51 
2.  F2 22.16 
3.  F3 16.57 
4.  F4 18.95 
5.  F5 21.66 
6.  F6 24.72 
 
Table 8Stability studies of tablets 
Test name Initial 1 Month 
300C/65 % RH 400C/75 % RH 
Description Yellow colour, round shaped, biconvex film coated tablets 
Average weight (mg) 825.06 825.33 825.51 
Thickness (mg) 5.58 5.58 5.58 
Hardness (kg/cm) 8.0-9.0 8.0-9.0 8.0-9.0 
Disintegration (min) 4.0-5.0 4.0-5.0 4.0-5.0 
Assay (%) 99.07 99.03 99.08 
Dissolution Time (min) % Drug Release 
5 66.8 54.5 57.3 
10 76.6 79.3 77.1 
15 83.1 85.2 83.8 
20 90.1 90.6 89.9 
30 98.9 99.1 98.5 
45 99.3 99.4 99.2 
60 99.5 99.4 99.5 
 
 
CONCLUSION 
 In the present work, an attempt was made to develop 
buffered tablet of rabeprazole sodium by direct compression 
and wet granulation method using sodium carbonate, 
sodium bicarbonate as a buffering agent, Crosspovidone as 
Super-disintegrants and mannitol as a diluents. Six 
formulations (F1-F6) were prepared, the optimum 
concentration were identified based on the disintegration 
time and in vitro drug release results. In the present study, 
pH of F 6 batch was found to be optimum and disintegration 
time is 42 sec. The drug release was found to show maximum 
drug release in case of F6 with 99.3% in 60 minutes. The 
results demonstrated the effective use of buffered tablet of 
rabeprazole and as an ideal drug release formulation for 
treatment of peptic ulcers and different acidic conditions. 
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